نتائج البحث - "Marianne T Sweetser"

1

Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1

المساهمون: Graduate School, APH - Methodology, APH - Quality of Care, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Paediatric Nephrology, ARD - Amsterdam Reproduction and Development

المصدر: New England journal of medicine, 384(13), 1216-1226. Massachussetts Medical Society

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c371005175d1307f379da84b8ad2b16fTest
http://www.scopus.com/inward/record.url?scp=85103565761&partnerID=8YFLogxKTest

2

Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects

المؤلفون: Husain Attarwala, Valerie A. Clausen, Pushkal Garg, Varun Goel, Verena Karsten, Gabriel J. Robbie, Megan Melch, Akshay Vaishnaw, Bahru A. Habtemariam, John Vest, Marianne T. Sweetser

المصدر: Clinical Pharmacology & Therapeutics. 109:372-382

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a926fdfa0bbe0b749b1e462a6eaad07dTest
https://doi.org/10.1002/cpt.1974Test

3

Patisiran, an RNAi therapeutic for patients with hereditary transthyretin‐mediated amyloidosis: Sub‐analysis in Japanese patients from the APOLLO study

المؤلفون: Matthew T. White, Masahisa Katsuno, Jing Jing Wang, Taro Yamashita, Mitsuharu Ueda, Tsuneaki Yoshinaga, Yoshiki Sekijima, Marianne T. Sweetser, Gen Sobue, Yukio Ando, Haruki Koike, Xiaoping Zhang, Minori Kodaira

المصدر: Neurology and Clinical Neuroscience. 8:251-260

مصطلحات موضوعية: Pathology, medicine.medical_specialty, biology, business.industry, Amyloidosis, medicine.disease, Transthyretin, Neurology, RNA interference, medicine, biology.protein, Neurology (clinical), business, Polyneuropathy, Attr amyloidosis

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1ce5b2f8eb0cedd5b6c483c79f2c3022Test
https://doi.org/10.1111/ncn3.12396Test

4

Long-term integrated safety of patisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy

المؤلفون: Matthew T. White, Michael Polydefkis, Marianne T. Sweetser, Angela Dispenzieri, John L. Berk, Jing Jing Wang, Julian D. Gillmore, Mathew S. Maurer, Alejandra González-Duarte, Seth Arum, Yoshiki Sekijima

المصدر: European Heart Journal. 41

مصطلحات موضوعية: medicine.medical_specialty, biology, business.industry, MedDRA, Mortality rate, Amyloidosis, Cardiomyopathy, Atrial fibrillation, medicine.disease, Gastroenterology, Transthyretin, Internal medicine, Cohort, medicine, biology.protein, In patient, Adverse effect, Cardiology and Cardiovascular Medicine, business, Polyneuropathy

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7b0521a23e3a0e4f52208d9be9a8155Test
https://doi.org/10.1093/ehjci/ehaa946.2129Test

5

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis

المؤلفون: Marianne T. Sweetser, Márcia Waddington-Cruz, Josep M. Campistol, Hartmut Schmidt, John L. Berk, Jing Jing Wang, Jared Gollob, David H. Adams, Teresa Coelho, Juan Buades, Michael Polydefkis, Jihong Chen, Ole B. Suhr, Isabel Conceição

المساهمون: Repositório da Universidade de Lisboa

المصدر: Orphanet Journal of Rare Diseases
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Orphanet Journal of Rare Diseases, Vol 15, Iss 1, Pp 1-10 (2020)

مصطلحات موضوعية: Tafamidis, medicine.medical_specialty, Neurologi, Cardiomyopathy, lcsh:Medicine, 030204 cardiovascular system & hematology, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, RNA interference, 0302 clinical medicine, NA interference, Polyneuropathy, Internal medicine, medicine, Humans, Prealbumin, ATTR amyloidosis, Pharmacology (medical), RNA, Small Interfering, Adverse effect, Genetics (clinical), Amyloid Neuropathies, Familial, biology, business.industry, Research, Amyloidosis, lcsh:R, General Medicine, medicine.disease, Discontinuation, Transthyretin, Neurology, chemistry, Concomitant, Quality of Life, Patisiran, biology.protein, business, 030217 neurology & neurosurgery

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ab76833c3c740a5a556579909bdfbdaTest
https://doi.org/10.1186/s13023-020-01399-4Test

6

Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

المؤلفون: Taro Yamashita, Jaclyn Franklin, Laura Obici, Julian D. Gillmore, Thomas H. Brannagan, Alejandra González-Duarte, Jihong Chen, Marianne T. Sweetser, Matthias Schilling, Peter D. Gorevic, Jing Jing Wang, Céline Labeyrie, David Adams, Hartmut Schmidt, Arnt V. Kristen, Teresa Coelho, John L. Berk, Senda Ajroud-Driss

المصدر: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP

مصطلحات موضوعية: Oncology, Adult, Male, medicine.medical_specialty, patisiran, Adolescent, hereditary transthyretin-mediated amyloidosis, 030204 cardiovascular system & hematology, 03 medical and health sciences, Polyneuropathies, Young Adult, 0302 clinical medicine, Quality of life, RNA interference, Internal medicine, APOLLO, Internal Medicine, Medicine, Humans, Prealbumin, Norfolk QOL-DN, In patient, RNA, Small Interfering, Aged, Aged, 80 and over, Amyloid Neuropathies, Familial, biology, business.industry, Amyloidosis, Middle Aged, medicine.disease, Placebo Effect, humanities, Multisystem disease, Transthyretin, quality of life, Mutation, biology.protein, Quality of Life, Female, business, 030217 neurology & neurosurgery